【】:目的 了解信迪利单抗致肺癌患者免疫相关不良反应的发生情况,进行回顾性研究,为临床安全用药提供参考。方法 研究对象选自2022年12月至2024年4月在内蒙古医科大学附属医院接受信迪利单抗的肺癌患者。检索医院电子病历信息,收集符合纳入标准患者的病历资料,患者性别、年龄、基础疾病、发生不良反应事件、不良反应发生时间、干预及预后等数据进行回顾性描述。结果 选取使用信迪利单抗治疗肺癌患者208例,发生33例不良反应,共41例次,累计器官10种,其中内分泌系统发生率最高14例次(14/41、34.1%)、肺炎9例次(9/41、22.0%),经治疗均已好转,无死亡病例。对信迪利单抗致肺癌患者发生不良反应进行单因素分析,吸烟、饮酒和联合化疗靶向洛铂有统计学意义。结论 信迪利单抗作为一种肿瘤治疗药物,其应用范围日益扩大。然而,伴随其使用的增加,免疫相关的不良反应也相应增多。尽管本研究中未出现致命的不良事件,但仍需保持高度警惕。及时识别并采取适当的干预措施,对于确保患者安全至关重要。

【】: Objective To understand the occurrence of immune-related adverse reactions in lung cancer patients caused by sindilizumab, a retrospective study was conducted to provide a reference for the safe use of the drug in the clinic. Methods The study subjects were selected from lung cancer patients who received sindilizumab from December 2022 to April 2024 at the Affiliated Hospital of Inner Mongolia Medical University. The hospital electronic medical record information was retrieved to collect the medical record data of patients who met the inclusion criteria, and the data on patients" gender, age, underlying disease, occurrence of adverse events, time of adverse events, intervention and prognosis were described retrospectively. Results 208 patients with lung cancer treated with sindilizumab were selected, and 33 adverse reactions occurred in 41 cases with 10 cumulative organs, including the highest incidence of endocrine system in 14 cases (14/41, 34.1%) and pneumonia in 9 cases (9/41, 22.0%), which have been improved by the treatment, and there is no percentage of death. A univariate analysis of the occurrence of adverse reactions in patients with lung cancer caused by sindilizumab, smoking, alcohol consumption and combination chemotherapy targeting Lopatin were statistically significant. Conclusion Sindilizumab is increasingly used as an oncology therapeutic agent. However, the increase in its use has been accompanied by a corresponding increase in immune-related adverse reactions. Although no fatal adverse events were observed in this study, a high level of vigilance is required. Timely recognition and appropriate interventions are essential to ensure patient safety.